• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

    134.32 -1.11 (-0.82%)
    Streaming Delayed Price Updated: 9:50 AM EDT, Oct 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Jazz Pharmaceuticals plc - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
    EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More
    Luxembourg: Medical Marijuana Shortage Due To Supplier Change 
    Via Benzinga
    Topics Cannabis Supply Chain
    Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio
    On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week. 
    Via Benzinga
    Topics Cannabis
    Where Jazz Pharmaceuticals Stands With Analysts
     
    Via Benzinga
    Expert Ratings for Jazz Pharmaceuticals
     
    Via Benzinga
    Where Jazz Pharmaceuticals Stands With Analysts
     
    Via Benzinga
    Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
    Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months 
    Via Benzinga
    Topics Cannabis
    Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report
    Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale. 
    Via Benzinga
    2 Top Biotech Stocks to Buy in October
    Growth catalysts lie ahead for both of these players. 
    Via The Motley Fool
    5 Genius Safe Stocks to Buy for the 4th Quarter of 2023
    These highly profitable, time-tested companies can deliver for their shareholders in any economic climate. 
    Via The Motley Fool
    4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
    An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound. 
    Via The Motley Fool
    Topics Stocks
    Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
     
    Via Benzinga
    3 Cannabis Stocks That Should Be on Every Investor’s Radar This Fall
    The cannabis industry is a quiet place where huge upside potential is building up. As more regions legalize, cannabis stocks can soar. 
    Via InvestorPlace
    Topics Cannabis
    Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
    FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
    Via FinancialNewsMedia
    3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
    Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
    Via InvestorPlace
    Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
    Via Investor Brand Network
    Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
    EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
    Via FinancialNewsMedia
    7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom
    Cannabis stocks re seeing renewed interest and these seven look like reasonable buys as rescheduling approaches for weed. 
    Via InvestorPlace
    Topics Cannabis
    Cannabis Industry Changes As Marijuana Rescheduling Looms
    As the Benzinga Cannabis Capital Conference returns to Chicago this Sept 27-28 for its 17th edition, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the top... 
    Via Benzinga
    Topics Cannabis
    NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
    NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
    Via Benzinga
    Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
    These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel. 
    Via The Motley Fool
    Topics Cannabis
    Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
    Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância... 
    Via Benzinga
    Topics Cannabis
    Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target
    Cantor Fitzgerald analyst Charles C. 
    Via Benzinga
    Cannabis Stock Gainers And Losers From August 11, 2023
     
    Via Benzinga
    Topics Cannabis
    Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year. 
    Via Benzinga
    3 Biotech Stocks You’ll Regret Not Buying Soon
    These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
     
    Via Benzinga
    GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job
    For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products. 
    Via Benzinga
    FDA, Get It Done! Says Senator In Bipartisan Push To Regulate CBD Products Prior To Committee Hearing
    A bipartisan group of U.S. lawmakers reintroduceda measure on Wednesdaythat aims to secure theFood and Drug ... 
    Via Benzinga
    Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
    Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say know, here is what happened. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.